Combined tablets of metformin and pioglitazone hydrochloride are available containing 500 mg of metformin and 15 mg of pioglitazone hydrochloride. Because metformin's insulin-sensitizing effect occurs mainly at the liver, combination with thiazolidinediones (TZDs), which mainly sensitize muscle to insulin-mediated glucose uptake, is a rational therapeutic strategy\[[@CIT1]\]

The aim of this paper was to explore the possibility of using techniques of absorbance ratio or Q-analysis method and derivative spectrophotometery methods for quantifying metformin and pioglitazone simultaneously in their mixture form. The advantage of these proposed methods is that no separation is required. The proposed procedures are simple, rapid and act as convenient alternative to HPLC method\[[@CIT2]\]

The absorption spectra of the reference and test solutions were recorded over the range of 200-400 nm keeping the solutions in 1 cm quartz cells using Shimadzu UV/Vis double beam spectrophotometer model 1700 Pharmaspec.

Gift samples of pure metformin and pioglitazone hydrochloride were procured from Zydus Cadila, Sikkim. Combined metformin and pioglitazone tablets (Pioz\*MF-15 containing metformin-500 mg and pioglitazone-15 mg and manufactured by USV Limited) were purchased from a local pharmacy. Analytical reagent grade hydrochloric acid, N,N-dimethyl formamide, distilled water was used as solvent. Stock solutions (500 μg/ml) of metformin and pioglitazone hydrochloride were prepared by dissolving separately 50 mg in 10 ml of N,N-dimethyl formamide in 100 ml volumetric flasks, and the volume was made up to 100 ml with 0.1 N hydrochloric acid.

In the quantitative assay of two components by Q-analysis method\[[@CIT3]\], absorbance were measured at two wavelengths, one being the isoabsorptive point and other being the wavelength of maximum absorption of one of the two components. From the overlain spectra of metformin and pioglitazone, 247.5 nm was the isoabsorptive point for both the drugs and other at 231 nm, the λ~max~for metformin was selected ([fig. 1](#F0001){ref-type="fig"}). The method employs Q-values, concentrations of drugs in sample solutions were determined using equation C~1~= (Q~0~-Q~2~)/(Q~1~-Q~2~)×(A/a~1~) for pioglitazone and C~2~= (Q~0~-Q~2~)/(Q~2~-Q~1~)×(A/a~2~) for metformin, where Q~0~= absorption of sample at 231 nm/absorption of sample at 247.5 nm, Q~1~= absorptivity of pioglitazone at 231 nm/absorptivity of pioglitazone at 247.5 nm, Q~2~= absorptivity of metformin at 231 nm/absorptivity of metformin at 247.5 nm, A= absorption of sample at isoabsorptive point and a~1~and a~2~= absorptivities of pioglitazone and metformin respectively at isoabsorptive point.
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In the derivative spectrophotometery\[[@CIT4]\] method solutions of 10 μg/ml of metformin and pioglitazone were prepared separately. Both the solutions were scanned in the spectrum mode from 400 to 200 nm. The absorption spectra thus obtained were derivatized from first to fourth order. First order derivative was selected for analysis of both the drugs. The zero crossing wavelengths, 269 and 231 nm were selected for pioglitazone and metformin respectively ([fig. 2](#F0002){ref-type="fig"}).
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For preparation of calibration curves five mixed standards having concentrations 0.5, 1, 1.5, 3 and 4.5 μg/ml of pioglitazone and 16.5, 33, 50, 100 and 150 μg/ml of metformin, respectively were prepared and scanned in the spectrum mode from 400 to 200 nm. The absorption spectra so obtained were derivatized to obtain first derivative order spectra. The absorbance of pioglitazone and metformin were measured at 269 and 231 nm, respectively and working calibration curves of both the drugs were plotted separately. The concentration of individual drug present in the mixture was determined against calibration curve in quantitation mode.

Twenty tablets were weighed accurately. The average weight was determined and then ground to a fine powder. A quantity equivalent to 15 mg of pioglitazone and 500 mg of metformin were transferred to a 100 ml volumetric flask. The contents were ultrasonicated for 10 min with solvent, made to volume and filtered through Whatmann filter paper. The solution was further diluted with solvent, to give concentration of μg/ml of pioglitazone and metformin, respectively. Absorbance of these solutions was measured at 269 nm and 231 nm, and concentration of pioglitazone and metformin obtained from standard calibration curve. Results of tablet analysis of the tablet formulation are reported in [Table 1](#T0001){ref-type="table"}. Accuracy, reproducibility and precision of the proposed method were studied with the help of recovery studies that was carried out by addition of standard drug solution to pre-analyzed sample.

###### 

ANALYSIS OF TABLET FORMULATION

  Method   Label Claim (mg/tablet)   Percent found (±SD)                 
  -------- ------------------------- --------------------- ------------- -------------
  DS       15                        500                   99.13±0.978   99.90±0.637
  QA       15                        500                   99.53±1.084   99.92±0.714

DS denotes derivative spectrophotometery and QA denotes Q-analysis. Pio represents pioglitazone hydrochloride and Met represents metformin hydrochloride. SD denotes standard deviation.

The proposed methods for simultaneous estimation of pioglitazone and metformin dosage forms were found to be simple, accurate, economical and rapid. In both the methods, the values of coefficient of variation were satisfactorily low and recovery was close to 100% ([Table 2](#T0002){ref-type="table"})for both the drugs. Hence it can be employed for routine analysis in quality control laboratories.

###### 

RECOVERY STUDY DATA OF TABLET FORMULATION

  Method   Level of % recovery   \% Recovery found   Standard deviation   Standard error                   
  -------- --------------------- ------------------- -------------------- ---------------- ------- ------- -------
           80                    99.87               100.27               0.554            1.286   0.320   0.743
           100                   99.85               99.20                0.528            1.311   0.305   0.757
           120                   99.91               99.47                0.581            1.249   0.337   0.721
           80                    99.71               99.33                0.140            1.331   0.081   0.768
           100                   99.85               99.20                0.466            1.587   0.275   0.916
           120                   99.91               99.47                0.689            1.514   0.408   0.874

DS denotes derivative spectrophotometery and QA denotes Q-analysis. Pio represents pioglitazone hydrochloride and Met represents metformin hydrochloride.
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